APA (7th ed.) Citation

Ban, T. H., Lee, S., Kim, H. D., Ko, E. J., Kim, B., Kim, K., . . . Yang, C. W. (2021). Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin. Stem Cells International, 1. https://doi.org/10.1155/2021/6672644

Chicago Style (17th ed.) Citation

Ban, Tae Hyun, Sua Lee, Hyung Duk Kim, Eun Jeong Ko, Bo-Mi Kim, Kyoung-Woon Kim, Byung Ha Chung, and Chul Woo Yang. "Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin." Stem Cells International 2021: 1. https://doi.org/10.1155/2021/6672644.

MLA (9th ed.) Citation

Ban, Tae Hyun, et al. "Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin." Stem Cells International, 2021, p. 1, https://doi.org/10.1155/2021/6672644.